NCT01181765View on ClinicalTrials.gov

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy

PHASE4CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Crohn's Disease
Interventions
BIOLOGICAL

Infliximab 5 mg/kg body weight infused over 2 hours

Subjects will receive IV Infusion of infliximab 5 mg/kg body weight at Week 0, Week 2, Week 6, Week 14 and Week 22 as per the approved Canadian product monograph of infliximab.

Trial Locations (2)

Unknown

Ottawa

Toronto

All Listed Sponsors
lead

Janssen Inc.

INDUSTRY

NCT01181765 - The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy | Biotech Hunter | Biotech Hunter